Driven to Deliver Innovative Treatments for Patients With Infectious Diseases

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections.
Learn More

PIPELINE &
RESEARCH

See Pipeline

PIPELINE & RESEARCH

Learn About Our Novel
Antibiotic Candidates

See Pipeline

FOR INVESTORS

Visit Investors Center

FOR INVESTORS

Find Shareholder News,
Events, & More

Visit Investors Center

CAREERS

View Jobs

CAREERS

Join Our Growing Team
at Nabriva

View Jobs

Collaborate With Us

We’re developing innovative therapies that have the potential to transform the lives of people with infectious diseases, and our current platform is just the beginning. We actively seek collaborators and licensing opportunities focused on the discovery, development, and commercialization of technologies and therapies that address infectious diseases. Contact us to learn more.

In the News

Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services
In the News

Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services
In the News

Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.